Forte Biosciences, Inc. — Director's Dealing 2017

Apr 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2017-04-19

Reporting Person: Das Asha (SVP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-19	Common Stock	P	2500	$10.00	Acquired	2500	Direct

Footnotes

F1: The shares were purchased at the Issuer's initial public offering.